ATE429233T1 - Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten - Google Patents

Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten

Info

Publication number
ATE429233T1
ATE429233T1 AT02751212T AT02751212T ATE429233T1 AT E429233 T1 ATE429233 T1 AT E429233T1 AT 02751212 T AT02751212 T AT 02751212T AT 02751212 T AT02751212 T AT 02751212T AT E429233 T1 ATE429233 T1 AT E429233T1
Authority
AT
Austria
Prior art keywords
glycoinhibitor
infectious diseases
against infectious
substance against
neutral glycan
Prior art date
Application number
AT02751212T
Other languages
English (en)
Inventor
Jari Natunen
Halina Miller-Podraza
Susann Teneberg
Jonas Angstroem
Karl-Anders Karlsson
Original Assignee
Glykos Finland Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20011403A external-priority patent/FI20011403A7/fi
Priority claimed from FI20011402A external-priority patent/FI20011402A7/fi
Application filed by Glykos Finland Oy filed Critical Glykos Finland Oy
Application granted granted Critical
Publication of ATE429233T1 publication Critical patent/ATE429233T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02751212T 2001-06-29 2002-06-28 Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten ATE429233T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20011403A FI20011403A7 (fi) 2001-06-29 2001-06-29 Menetelmä ja koostumukset vatsan sairauksien hoitoon
FI20011402A FI20011402A7 (fi) 2001-06-29 2001-06-29 Lääkkeet ja hoitotavat patogeenejä vastaan
PCT/FI2002/000574 WO2003002127A1 (en) 2001-06-29 2002-06-28 Use of at least one glycoinhibitor substance

Publications (1)

Publication Number Publication Date
ATE429233T1 true ATE429233T1 (de) 2009-05-15

Family

ID=26161191

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751212T ATE429233T1 (de) 2001-06-29 2002-06-28 Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten

Country Status (7)

Country Link
US (1) US20040176320A1 (de)
EP (1) EP1411952B1 (de)
JP (1) JP2005504017A (de)
AT (1) ATE429233T1 (de)
AU (1) AU2002352531A1 (de)
DE (1) DE60232077D1 (de)
WO (1) WO2003002127A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537976A (ja) 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
US20060014717A1 (en) * 2002-06-28 2006-01-19 Glykos Finland Oy Therapeutic compositions for use in prophylaxis or treatment of diarrheas
JP4918361B2 (ja) † 2003-10-13 2012-04-18 ネステク ソシエテ アノニム エンドトキシンの作用の緩和
WO2007036041A1 (en) * 2005-09-28 2007-04-05 Suleiman Igdoura Sialidase inhibitors for the treatment of cardiovascular disease
JP5035787B2 (ja) * 2005-10-04 2012-09-26 焼津水産化学工業株式会社 α−１、４結合型Ｎ−アセチルグルコサミン含有Ｏ−グリカン型糖鎖の分泌促進剤並びにこれを含有するヘリコバクターピロリ菌を原因とする病態の治療予防剤
AU2007290570C1 (en) 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies
JP5014018B2 (ja) * 2006-10-18 2012-08-29 旭化成ケミカルズ株式会社 ピロリ菌の抑制剤または静菌剤
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
EP2060257A1 (de) * 2007-11-08 2009-05-20 Nestec S.A. Vorbeugung und Behandlung von Sekundärinfektionen nach Virusinfektion
ES2658837T3 (es) * 2008-03-14 2018-03-12 Nestec S.A. Mezcla simbiótica
US9301540B2 (en) * 2008-06-09 2016-04-05 Georgia-Pacific Panel Products Llc Prebiotic composition and methods of making and using the same
GB0817908D0 (en) 2008-10-01 2008-11-05 Univ Ghent Blood group a/b/h determinant on type 1 core glycosphinglipids chain as recognition point for the fedf protein of f18-fimbriated enterotoxigenic
US9678005B1 (en) * 2008-12-03 2017-06-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Devices and methods for detection of microorganisms
US8785402B2 (en) * 2009-07-31 2014-07-22 Academia Sinica Compositions and assays for treatment and diagnosis of helicobacter pylori infection and conditions
WO2011031531A2 (en) 2009-08-27 2011-03-17 Temple-Inland Methods of making and using a ruminant gas reduction composition
WO2011072051A2 (en) 2009-12-08 2011-06-16 Temple-Inland Nutritional composition and methods of making and using same
KR101784539B1 (ko) * 2010-01-28 2017-10-11 랩터 파마슈티컬스 인코포레이티드 수용체 결합 단백질(ｒａｐ) 펩타이드-푸코시다제 억제제 접합체를 이용한 간 질환의 치료방법
DK2549994T3 (en) 2010-03-25 2015-11-09 Bioglane S L N E Use of D-phagomin as an inhibitor of bacterial adhesion to epithelial cells
US20180195035A1 (en) * 2014-02-12 2018-07-12 Goddard Labs, Inc. Rapid Detection of Human Pathogens in Plant Material Or Water
US9994605B2 (en) 2014-03-13 2018-06-12 Universitaet Basel Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein
KR101613964B1 (ko) 2014-05-20 2016-04-21 농업회사법인 주식회사 생명의나무 글라이코매크로펩타이드 효소분해물을 유효성분으로 하는 헬리코박터 파이로리 감염 예방 또는 치료용 조성물
CA2996073A1 (en) 2015-09-16 2017-03-23 Universitat Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
EP3184536A1 (de) * 2015-12-22 2017-06-28 Westfälische Wilhelms-Universität Münster Oligosaccharidzusammensetzung zum binden an lectine
WO2017109587A1 (en) * 2015-12-22 2017-06-29 Universidad Nacional De Colombia "glycoinhibitors of adherence" of streptococcus in fish
CN112672764A (zh) * 2018-06-19 2021-04-16 格莱科斯生物医药公司 结合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK17885D0 (da) * 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
US5217715A (en) * 1988-08-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Carbohydrate receptor for bacteria and method for use thereof
US5242800A (en) * 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
WO1994018986A1 (en) * 1993-02-26 1994-09-01 Jan Staffan Normark Use of oligosaccharide glycosides as inhibitors of bacterial adherence
DE4408248A1 (de) * 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
US5665561A (en) * 1994-06-06 1997-09-09 The Rockefeller University Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications
US5641760A (en) * 1994-06-17 1997-06-24 Pence, Inc. Method of treating candida infection
EP0918526A1 (de) * 1996-05-03 1999-06-02 Neose Technologies, Inc. Bismuthsalz von sialyloligosaccharid und verfahren zur behandlung von magen- und duodenalgeschwürer damit
SE9901007D0 (sv) * 1999-03-19 1999-03-19 Thomas Boren Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence
US6664235B1 (en) * 1999-08-20 2003-12-16 Riken Medicaments comprising sialic acid derivatives as active ingredients
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof

Also Published As

Publication number Publication date
EP1411952A1 (de) 2004-04-28
JP2005504017A (ja) 2005-02-10
WO2003002127A1 (en) 2003-01-09
US20040176320A1 (en) 2004-09-09
AU2002352531A1 (en) 2003-03-03
DE60232077D1 (de) 2009-06-04
EP1411952B1 (de) 2009-04-22

Similar Documents

Publication Publication Date Title
ATE429233T1 (de) Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
BR9812381A (pt) Peptopiranosilnucleosìdeo, seu preparo e uso
PT1333887E (pt) Metodo de tratamento de desordens musculares
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
DE59611341D1 (de) Verwendung von saccharid-konjugaten
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
BR0206568A (pt) Novo método e composições para o tratamento local de doença de meniere, de zumbido no ouvido e/ou de perda de audição
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
PT998287E (pt) Utilizacao de levobupivacaina
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
DK1368019T3 (da) Esmololformulering
DE59904180D1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler
DE60128100D1 (de) Analgetisches arzneimittel
CY1119257T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda)
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
SE0004101D0 (sv) New use
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties